Phaarmasia Ltd (PHRMASI) is currently trading at 119.45 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Phaarmasia Limited, established in 1981, specializes in manufacturing and marketing oral contraceptive tablets and iron tablets, primarily serving the Ministry of Health & Family Welfare and export markets. The company boasts a state-of-the-art manufacturing facility with a capacity exceeding 30 million units annually, meeting WHO-GMP and ISO 9001 certification standards. Historically faced challenges, particularly in 2000 when it was classified as a Sick Industrial Company under SICA, indicating financial distress at the time. Part of Maneesh Pharmaceutical Limited, Phaarmasia operates independently, ensuring high-quality production in a dust-free, hygienic environment.

Over the past 52 weeks, Phaarmasia Ltd has traded between a low of ₹23.60 and a high of ₹131.75. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Phaarmasia Ltd has a market capitalization of approximately 81.58. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Phaarmasia Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 104.78 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

You can buy shares of Phaarmasia Ltd (PHRMASI) through any SEBI-registered stockbroker in India. A demat and trading account are required to place buy or sell orders on stock exchanges such as NSE or BSE. Shares are credited to the demat account as per the exchange settlement cycle.

Based on its market capitalization of 81.58 Cr, Phaarmasia Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Phaarmasia Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Phaarmasia Ltd is 104.78. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Phaarmasia Ltd currently does not pay dividends. Companies that do not pay dividends often reinvest profits to support business growth or strengthen operations.

Key risks associated with Phaarmasia Ltd include sector-specific challenges in the Pharmaceuticals industry, regulatory changes, competitive pressures, company-level financial performance, overall market volatility, and broader macroeconomic factors that can impact stock prices.